Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In this module I teach you all about what you need to do to be successful on a GLP-1 AND as a surgical bariatric patient.
10.1016/j.molmet.2018.09.009 19 DeganuttiG.LiangY
For mild local injection site reactions : Apply a cold compress to the affected area to reduce swelling and discomfort Avoid rubbing or scratching the injection site Monitor the reaction over 2448 hours for any worsening Contact your GP or diabetes specialist nurse if symptoms persist beyond 72 hours, spread beyond the injection site, or cause significant discomfort If symptoms are mild and self-limiting without systemic features, continue to monitor but discuss with your healthcare team before making any treatment changes For moderate systemic reactions (such as widespread hives or mild facial swelling without breathing difficulty): Stop using the medication immediately and do not take further doses Contact your GP urgently or call NHS 111 for advice Take an oral antihistamine if available and previously tolerated (such as cetirizine or loratadine) Seek same-day medical assessment to determine whether the medication should be discontinued and to discuss alternative treatment options For severe reactions or suspected anaphylaxis (difficulty breathing, throat swelling, collapse, or rapid symptom progression): Call 999 immediately and request an ambulance Use an adrenaline auto-injector if one has been prescribed and you have been trained in its use Lie flat with legs elevated (unless breathing is difficult, in which case sit upright) Do not attempt to drive yourself to hospital Inform paramedics and hospital staff about the GLP-1 agonist and timing of the last dose Following any allergic reaction, it is important to report the event to your healthcare team
You must adjust your calculations to reflect only the active ingredient
In terms of lipid profile, the LC group had markedly higher levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (Apo-A1) than those receiving the placebo
